136 results about "Squamous Cell Cancers" patented technology

The invention discloses a method for analyzing the tumor microenvironment of esophageal squamous cell carcinoma. The method comprises the following steps: selecting a basic tissue structure protein to be analyzed in a tumor microenvironment, carrying out cell segmentation and protein expression level extraction, carrying out clustering identification on cell types, identifying a three-level lymph structure and a neighborhood thereof, and determining an immune cell proportion and an expression level of a key functional protein. Identifying tissue regions and neighborhoods thereof and determining different cell proportions and expression levels of key functional proteins, as well as determining cell-cell spatial interactions in the tumor microenvironment. The method provided by the invention can greatly improve the efficiency and accuracy of predicting the intervention effect.

The invention relates to a multi-modal survival prediction method fusing a digital pathological image and omics data. The method comprises the following steps: acquiring a full-view digital pathological image and omics data of an esophageal squamous cell carcinoma patient; carrying out preprocessing and feature extraction on the full-view digital pathological image and the omics data to respectively obtain a pathological embedding representation and an omics embedding representation; fusing the pathological embedding representation and the omics embedding representation by using a multi-head attention mechanism of Transform to obtain a preliminary fusion feature; performing deep interaction on the pathological embedding representation and the preliminary fusion feature to obtain a final fusion feature; and predicting a survival result based on the final fusion feature. According to the method, bimodal sharing of pathological images and omics data and full fusion of features are realized, and prognosis survival prediction of esophageal squamous cell carcinoma cancer patients can be better realized.

The invention discloses a construction method of a model for predicting an esophageal squamous cell carcinoma intervention effect. The construction method comprises the following steps: acquiring detection data of a predictive factor in a sample; the predictive factors at least comprise the content or the expression level of a depletion marker of a functional CD8 T cell in a sample and the content or the expression level of a C1QC + macrophage immune checkpoint molecule; and predicting the intervention effect of the esophageal squamous cell carcinoma according to the detection data of the predictive factor. Establishing a space proteomics map of a complex space tissue of a tumor microenvironment (TME) during treatment; key spatial features which are related to specific cell behaviors and influence treatment results are determined and layered; a powerful prediction model of drug response is developed by utilizing a machine learning technology, and the area under curve (AUC) can reach 97%.

The present invention relates to immunoconjugates specific for human EPH receptor A5 (EphA5), methods of treatment of cancers (e.g., carcinomas including squamous cell carcinoma, and colorectal cancer) using said immunoconjugates, and related pharmaceutical compositions of said immunoconjugates.

The invention discloses application of circular RNA (Ribonucleic Acid) Hsacirc0006332 in diagnosis and treatment of esophageal squamous cell carcinoma, and belongs to the field of biological medicines. The application comprises the application of a reagent capable of detecting the Hsacirc0006332 or the expression quantity of the Hsacirc0006332 in preparation of a kit for diagnosing the esophageal squamous cell carcinoma, and the nucleotide sequence of the Hsacirc0006332 is SEQ ID NO. 1. The invention further discloses application of the component capable of inhibiting or blocking expression of the Hsacirc0006332 in preparation of a medicine for treating esophageal squamous cell carcinoma. The expression level of Hsacirc0006332 specific siRNAs in esophageal squamous cell carcinoma cells is changed through molecular biology means such as construction of Hsacirc0006332 specific siRNAs, and it is revealed that interference on Hsacirc000632 expression can significantly inhibit proliferation, invasion and migration of esophageal squamous cell carcinoma cells and promote tumor cell biological phenotypes such as cancer cell apoptosis. Therefore, the Hsacirc0006332 can be used as a therapeutic target to be applied to preparation, screening or treatment of esophageal squamous cell carcinoma or inhibition of esophageal squamous cell carcinoma migration invasion, and a new therapeutic method is provided for intervention or treatment of esophageal squamous cell carcinoma.

The invention belongs to the technical field of biological medicine, and provides self-assembled polypeptide targeting mitochondria, a preparation method and application of the self-assembled polypeptide, a self-assembled polypeptide microneedle patch and a preparation method of the self-assembled polypeptide microneedle patch. According to the self-assembly polypeptide of the targeted mitochondria, the amino acid sequence is GFFGKXRXKXRX, and X represents cyclohexyl alanine. A targeting peptide (Mito) sequence KXRXKXRX can recognize cell mitochondria in a targeting manner, a self-assembly sequence GFFG is introduced to an N terminal of the Mito sequence KXRXKXRX, and the targeting peptide sequence is endowed with a self-assembly capability, so that the self-assembly polypeptide can cause morphological function abnormality of mitochondria in tumor cells, the tumor cells are killed, and inhibition of the tumor cells is realized. The self-assembled polypeptide disclosed by the invention is applied to treatment of tumor cells through in-situ administration of the self-assembled polypeptide microneedle patch. Oral squamous cell carcinoma serves as a highly proliferated tumor cell, rapid proliferation of the oral squamous cell carcinoma needs a large amount of energy supply for mitochondria, and therefore attacking of the mitochondria can serve as an effective treatment target.

Targeting metastasis stem cells through a fatty acid receptor. The disclosure provides the use of blockers or inhibitors of CD36 activity or expression for the treatment of oral squamous cell cancer (OSCC), particularly for the treatment of generated metastases and for diminish is generation from primary tumours. Apart from shRNAs, anti-CD36 antibodies are provided as blockers or inhibitors, especially those that block the binding of CD36 to oxidized LDL and fatty acids and their incorporation into cells, because the promotion of their transport is indicated as the mechanism by which CD36 promote metastases dissemination and growth. Also provided is a method for identifying candidates to anticancer agents, particularly for OSCC metastasis, among those that promote in CD36+ cells, in vivo or in vitro, effects associated to CD36 depletion or blocking such as decrease of growth accumulation of lipid droplets and decrease of size in the case of metastases.

The application discloses a photosensitizer conjugate for targeted treatment of tongue squamous cell carcinoma and a preparation method and application thereof, and belongs to the technical field of biological medicines. A novel PROTAC-PDT conjugate Gef-PRO-SS-TPE is synthesized, and the compound connects a PROTAC molecule Gef-PRO targeting EGFR and an AIE photosensitizer TPE derivative through a breakable disulfide bond. On one hand, Gef-PRO can specifically degrade EGFR and block tumor cell proliferation signals; on the other hand, the TPE derivative can generate ROS under light conditions and induce cell apoptosis. More importantly, the disulfide bond can be broken in response to high concentrations of glutathione (GSH) in tumor cells, realizing controllable release of Gef-PRO and TPE molecules, so as to exert a synergistic anti-tumor effect.

To provide anti-New York esophageal squamous cell carcinoma 1 (NY-ESO-1) antigen-binding proteins and methods of using the same.SOLUTION: The present disclosure provides antigen-binding proteins that specifically bind to an HLA-displayed New York esophageal squamous cell carcinoma 1 (NY-ESO-1) peptide, and therapeutic and diagnostic methods of using those binding proteins. The antigen-binding proteins of the present disclosure bind with a high degree of specificity to HLA-displayed NY-ESO-1 and do not bind to HLA-displayed peptides that differ by 2, 3, 4, 5, or more amino acids.SELECTED DRAWING: None

The present invention relates to a method of predicting the vulnerability of a squamous cell carcinoma (SCC) to inhibition by a PI3K inhibitor, preferably by a PI3K / mTOR inhibitor, including the selection of the patient predicted to benefit from therapeutic administration with the PI3K inhibitor, preferably of the PI3K / mTOR inhibitor. Moreover, the present invention relates to a method of treating a squamous cell carcinoma (SCC) of a mammal, preferably a human patient, comprising administering a therapeutically effective amount of a PI3K inhibitor, preferably a therapeutically effective amount of a PI3K / mTOR inhibitor to said mammal, preferably said human patient. Furthermore, the present invention relates to pharmaceutical compositions and kits associated with the inventive methods.

The invention relates to the technical field of microorganisms, and particularly discloses a product for predicting tumor cell occurrence and metastasis risks and treating tumors by using a microbial marker. The cancers related to the invention comprise colon adenocarcinoma, head and neck squamous cell carcinoma, renal clear cell carcinoma, renal papillary cell carcinoma, hepatocellular carcinoma, lung squamous cell carcinoma, prostate adenocarcinoma, gastric adenocarcinoma, thyroid carcinoma, breast invasive carcinoma, uveal melanoma, esophageal carcinoma and the like. As a marker for predicting the occurrence and metastasis risk of tumor cells. The invention also screens specific microorganisms of healthy tissues relative to tumor tissues as potential means for treating tumors. The screened flora marker is high in sensitivity and good in specificity, and a new method is provided for tumor cell generation and metastasis monitoring and tumor treatment.

The present disclosure provides anti-ULBP2 antibodies or antigen binding fragments thereof, including bispecific. The antibodies are administered in combination with a chemotherapy agent, a radiation therapy, and / or an immune checkpoint inhibitor for treatment of basal squamous cancer. The present disclosure also relates to methods and kits for detecting a predisposition to, determining the risk of, and guiding therapy for ULBP2 related disorders.

The invention relates to the technical field of tumor molecular biology. The invention provides application of CTLA-4, TIM-3 and LAG-3 as immune checkpoints in screening of drugs for treating oral squamous cell carcinoma. According to the invention, expression differences of CTLA-4, TIM-3 and LAG-3 in oral squamous cell carcinoma tissues and normal tissues and correlation between expression of CTLA-4, TIM-3 and LAG-3 and CD8 + T cell infiltration are compared and analyzed, CTLA-4, TIM-3 and LAG-3 are screened as suitable immune checkpoints, and by inhibiting expression levels of CTLA-4, TIM-3 and LAG-3, activation and proliferation of T cells can be improved, positive regulation immune response can be increased, and the immunologic function of the oral squamous cell carcinoma is enhanced. Therefore, the oral squamous cell carcinoma treatment effect is improved.

The invention relates to application of WDR74 and / or ALYREF as molecular targets in esophageal squamous cell carcinoma diagnosis and treatment, and belongs to the technical field of biological medicine. Aiming at the problem that the esophageal squamous cell carcinoma lacks an effective targeted treatment means, the invention discovers that the expression quantity of WDR74 in tumor tissues is obviously higher than that in para-carcinoma tissues, and the high expression of WDR74 prompts poor prognosis of a patient, and reveals that WDR74 protein and ALYREF protein have specific binding, and the mRNA stability of EGFR is enhanced through ALYREF-mediated m5C RNA epigenetic modification, so that STAT3 phosphorylation is activated, and the treatment effect of the esophageal squamous cell carcinoma is enhanced. Further, the STAT3 is combined with the promoter region of the apoptosis-inhibiting gene MCL1, and finally cell apoptosis is inhibited and tumor formation is promoted. The invention provides a new molecular target and a solution for developing a WDR74 and ALYREF targeting medicine for treating esophageal squamous cell carcinoma and related diagnosis and prognosis evaluation products.

The invention relates to application of lactobacillus muricatum in preparation of a medicine for treating oral cancer, the oral cancer is oral squamous cell carcinoma, a C57BL / 6 mouse tongue squamous cell carcinoma model induced by a 4-NQO water drinking method and a C3H / HeN subcutaneous tumor model inoculated by SCC7 tumor cells are constructed, and the lactobacillus muricatum has a remarkable inhibition effect on the oral cancer; experiments prove that the number / area / volume / weight of tumors is remarkably reduced by the lactobacillus muricatum, tumor marginal infiltration and abnormal karyokinesis are effectively inhibited, the expression quantity of tumor proliferation markers is remarkably reduced, and obvious pathological changes do not appear in main organs (heart, liver, spleen, lung and kidney) of mice. The method for minimally invasive injection of the lactobacillus muricatum into the oral squamous cell cancer tumor is safe, drug resistance is not easily induced, the treatment scheme is standardized, and the method has good clinical application potential.

The present disclosure relates to methods for predicting the risk of recurrence and / or metastasis, or both in primary cutaneous squamous cell carcinoma (cSCC).

The present disclosure relates to detecting one or more types of oropharyngeal cancer in a biological sample from a subject. In particular, the present disclosure provides compositions and methods for detecting the presence or absence of one or more types of oropharyngeal cancer (e.g., HPV+ oropharyngeal squamous cell cancer) in a biological sample from a subject having or suspected of having an oropharyngeal cancer.

The present invention belongs to the field of biomedicine technology, and discloses the use of a quercetin derivative Q3MG in the preparation of anti-tumor invasion and metastasis drugs and drugs for targeted degradation of pro-IL-1β protein in cancer cells. The present invention first discovered that Q3MG can significantly inhibit tumor invasion and metastasis by targeted degradation of pro-IL-1β protein in cancer cells, and has a good therapeutic effect on anti-tumor invasion and metastasis, especially squamous cell carcinoma; it reveals the importance of quercetin derivatives in the preparation of drugs for the treatment of squamous cell carcinoma invasion and metastasis, and even the potential value of flavonoid compounds in various other tumors, which has far-reaching clinical significance and important prospects for promotion and application.

The present disclosure provides antigen-binding proteins that specifically bind to an H LA-displayed New York esophageal squamous cell carcinoma 1 (NY-ESO-1) peptide, and therapeutic and diagnostic methods of using those binding proteins. The antigen-binding proteins of the present disclosure bind with a high degree of specificity to HLA-displayed NY-ESO-1 and do not bind to HLA-displayed peptides that differ by 2, 3, 4, 5 or more amino acids.

The application provides an oxazinane compound, a preparation method, a pharmaceutical composition and application, and a general formula of the oxazinane compound or a pharmaceutically acceptable salt thereof is shown as formula (I). The oxazinane compound has obvious proliferation inhibition effect on cancer cells, especially human head and neck squamous cell carcinoma cell strains HSC4, HSC3, HSC2, CAL33, SCC4 and human glioma cell strain U251, can block the cell cycle, effectively inhibit the phosphorylation level of key proteins in the PI3K / AKT / mTOR pathway at the molecular level, has the potential to be prepared into a new antitumor drug, and has a good market prospect.

The invention discloses an anti-PIK3IP1 nano antibody and application thereof, and relates to the technical field of biological medicines. The anti-PIK3IP1 nano antibody screened from a bactrian camel VHH immune library can be specifically combined with a PIK3IP1 antigen, and it can be known through determination of the affinity of the antibody that the affinity of the obtained nano antibody ranges from 10 <-8 > M to 10 <-7 > M order of magnitude, and the affinity is high. The nano antibody or the antigen binding fragment can be specifically bound with PIK3IP1, can be prepared into medicines for preventing or treating various tumors such as lung cancer, liver cancer, colorectal cancer, breast cancer, glioma, stomach cancer, esophagus cancer, oral squamous cell carcinoma or head and neck cancer, and has a wide application prospect.

The present disclosure relates to a novel method of treating squamous cell carcinoma (SCC), and in particular head and neck squamous cell carcinoma (HSSCC) and cutaneous carcinoma (CC) using MUC1-C inhibitors. Also described herein is a novel method of suppressing the progression of premalignant lesions to a squamous cell carcinoma.

The present invention relates to an application of a reagent for detecting a biomarker in preparing a product for diagnosing oral squamous cell carcinoma, wherein the reagent for detecting a biomarker comprises a reagent for detecting one or more of miR-331-3p, miR-642a-5p and miR-1282, wherein the reagent for detecting hsa-miR-331-3p, hsa-miR-642a-5p and hsa-miR-1282 is a primer, the upstream primer for detecting hsa-miR-331-3p is shown in SEQ ID NO: 2, the upstream primer for detecting hsa-miR-642a-5p is shown in SEQ ID NO: 3, the upstream primer for detecting hsa-miR-1282 is shown in SEQ ID NO: 4, and the downstream universal primer for detecting hsa-miR-331-3p, hsa-miR-642a-5p and hsa-miR-1282 is shown in SEQ ID NO: 5. The present invention finds that hsa-miR-331-3p is significantly highly expressed in oral squamous cell carcinoma and can be used as a potential biomarker for oral squamous cell carcinoma; the present invention finds that after down-regulating the expression of hsa-miR-331-3p, it can significantly inhibit the proliferation and invasion of oral squamous cell carcinoma cells and can be used as a potential target for the treatment of oral squamous cell carcinoma.

The invention relates to a methylation site marker for assisting in early diagnosis of esophageal squamous cell carcinoma and application of the methylation site marker, and belongs to the technical field of biomedicine. The methylation site marker is one or a combination of human peripheral blood mononuclear cell methylation sites cg05064044, cg03395511 and cg21548813, and the nucleotide sequence of the methylation site marker is as shown in SEQ ID NO. 1-3. According to the present invention, the methylation chip detection results show that the methylation levels of the cg05064044, the cg03395511 and the cg21548813 in the peripheral blood mononuclear cells of the esophageal squamous cell carcinoma patient are significantly increased compared to the health control group; the methylation levels of cg05064044, cg03395511 and cg21548813 sites in PBMC of esophageal squamous cell carcinoma patients in a training queue and a verification queue are all obviously higher than those of a healthy control group through further analysis. Finally, through ROC curve analysis, it is determined that the three methylation sites cg05064044, cg03395511 and cg21548813 have good specificity and sensitivity, have high diagnosis efficiency when being independently or jointly used for esophageal squamous cell carcinoma diagnosis and can be used as potential molecular markers for esophageal squamous cell carcinoma diagnosis.

The invention relates to a computer-implemented method for detecting oesophageal squamous cell dysplasia (OSCD) or oesophageal squamous cell cancer (OSCC) in a cell sample from a subject. This invention also relates to a computer-implemented method for generating a trained model to detect OSCD or OSCC. This invention also relates to a computer-readable storage medium or a computer program comprising instructions which when executed by a computer, are capable of causing the computer to perform the method. This invention also relates to a kit comprising the computer program or computer-readable storage medium and a non-endoscopic cell collection device. The invention also relates to an apparatus for performing the method. The invention further relates to the use of genome wide instability scores (GWIS) as a diagnostic marker for cancer, wherein GWIS is a measure of the CNV across a plurality of autosomal arms in a cell sample from a subject.

The present invention belongs to the technical field of medicinal chemistry, specifically relates to a compound capable of binding to a CRBN protein and a composition thereof, and also relates to a protein degradation agent based on a CRBN protein and the use thereof. Specifically disclosed is a compound capable of binding to a CRBN protein, wherein the compound is composed of two sub-structure units A and B, the two sub-structures A and B are connected by means of a chemical single bond between Y of the sub-structure A and one of C2 (carbon at position 2), C4 (carbon at position 4), C5 (carbon at position 5), C6 (carbon at position 6) and C7 (carbon at position 7) of the sub-structure B, and the compound is as shown in formula I. The compound can be used as a structural unit of an E3 ubiquitin ligase ligand in PROTAC technology, thereby providing more therapeutic means for cancers or diseases such as prostate cancer, breast cancer, non-small cell lung cancer, Alzheimer's disease, neuroblastoma, hepatocellular carcinoma, colorectal cancer, pancreatic cancer, malignant rhabdomyosarcoma, and oral squamous cell carcinoma.

The present disclosure relates to a novel method of treating squamous cell carcinoma (SCC), and in particular head and neck squamous cell carcinoma (HSSCC) and cutaneous carcinoma (CC) using MUC1-C inhibitors. Also described herein is a novel method of suppressing the progression of premalignant lesions to a squamous cell carcinoma.

The invention belongs to the technical field of medicines, and particularly discloses an oral squamous cell carcinoma inhibitor and application thereof. The inhibitor takes rutin as an active component. In-vitro experiments prove that rutin can significantly inhibit proliferation, clone formation, migration and invasion ability of OSCC cells in a dose-dependent manner, and effectively induce cell apoptosis. The action mechanism of the rutin is as follows: the rutin can directly target STAT3 protein and inhibit phosphorylation of the STAT3 protein so as to regulate and control a downstream BCL2 / CASP3 apoptosis pathway, thereby playing a role in treating OSCC. Molecular docking results further show that rutin and STAT3 have strong binding capacity. The invention discloses a new application of rutin as an STAT3 inhibitor in treating oral squamous cell carcinoma, and provides a new strategy and a candidate compound for developing high-efficiency and low-toxicity OSCC treatment medicines.

This invention discloses a method and system for two-dimensional image segmentation and benign / malignant differentiation of oral squamous cell carcinoma, belonging to the field of two-dimensional image processing technology for oral squamous cell carcinoma. It aims to improve the accuracy and stability of early screening for oral squamous cell carcinoma. The invention acquires oral image data, labels the acquired images according to pre-set classification standards to obtain training and testing sets; preprocesses the oral image data to obtain preprocessed training and testing sets; performs data augmentation on the oral image data in the training set to obtain a data-augmented training set; constructs an image feature extraction model based on a convolutional neural network; and trains the convolutional neural network-based image feature extraction model using supervised learning to obtain a trained convolutional neural network-based image feature extraction model for two-dimensional image segmentation and benign / malignant differentiation of oral squamous cell carcinoma.

The invention relates to the technical field of medical detection. The invention aims to provide a nano-probe for detecting the expression of an epidermal growth factor receptor of head and neck squamous carcinoma cells. The nano-probe is a nano-particle with a core-shell structure, the nano particle takes a nano Au particle as a core, and 4-mercaptobenzoic acid (4-MBA) is adsorbed on the surface of the Au core as a Raman signal internal reference molecule; according to the nanoparticle, SiO2 is used as a shell, and PEG and EGFR antibodies are linked to the SiO2 shell. According to the nanoprobe, head and neck squamous cell cancer cell and tissue imaging is researched by adopting a surface enhanced Raman spectroscopy technology, tumor cell and tissue EGFR expression images are drawn, and quantitative analysis and research are carried out. A rapid, visual and accurate new tool is provided for clinically detecting the squamous cell carcinoma of the head and neck and the EGFR expression condition of the squamous cell carcinoma of the head and neck.